Anifrolumab (MDX-1333)

Powder: -20 degree C for 3 years | In solvent: -80 degree C for 1 year

DMSO: 60 mg/mL (144.07 mM)
Need ultrasonic
(< 1 mg/ml refers to the product slightly soluble or insoluble)

1326232-46-5

ISRE: 0.3?nM

Anifrolumab induces sustained reduction of surface IFNAR1 and abrogates STAT1 phosphorylation at a concentration of 67.7?nM for 20 minutes[1]. Anifrolumab suppresses the differentiation of B cells into plasma cells at concentrations of 1 and 10ug/mL for 6 or 7 days[1]. Anifrolumab inhibits type I IFN-induced ISRE signaling, with IC50s ranging from 0.004 to 0.3?nM for the IFN-alpha subtypes, and 0.03?nM and 0.07?nM for IFN-beta and IFN-omega, respectively[1].At a concentration of 67.7?nM, Anifrolumab dose-dependently inhibits IFN-alpha production from pDCs in response to CpG-A or DNA-IC stimulation, inhibiting 87-95% of IFN-alpha production[1].